Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

INDOLE ANALOGS AS NOVEL APPETITE SUPPRESSANTS

Award Number: R44DK065322
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/20/2010
PERIOD OF PERFORMANCE END DATE: 06/30/2010

Group Awards By:

View Award Description

INDOLE ANALOGS AS NOVEL APPETITE SUPPRESSANTS - DESCRIPTION (provided by applicant): Obesity affects millions of people in the U.S. and worldwide, and this disease has enormous health and economic consequences for our society. Existing treatments show limited efficacy, can possess troubling side effects, and often require long-term therapy. Discovery of a new treatment for obesity would have a very considerable scientific and commercial value. One approach to pharmacotherapy for appetite suppression is the development of 5-HT2C receptor agonists, which was the focus of our Phase One work. In Phase Two, we propose to optimize and further develop these leads through a Structure-Activity Relationship (SAR) program of synthesis and biological evaluation. From this project we specifically aim to discover one or more indole analogs showing efficacy in our animal model for appetite suppression that is equal to or better than approved medications. Such leads will also display favorable drug-like properties. The long-term goal of this project is to discover a new, improved pharmaceutical agent for treatment of obesity that can be licensed and developed for ultimate market approval. 7. Project Narrative Obesity is a serious health problem in the Unites States, and the existing drugs to help people lose weight are often not effective and have side effects. We are carrying out research to discover and develop a new drug for obesity. If we are successful, doctors will have another option to help obese people with their weight problem.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2010 ( Subtotal = $96,281 )
2010	2010	ORGANIX, INC	240 SALEM STREET	WOBURN	MA	01801	MIDDLESEX	USA	Trans-NIH Recovery Act Research Support	001	4	1/18/2010	SUPPLEMENT FOR EXPANSION	$96,281
2010	2008	ORGANIX, INC	240 SALEM STREET	WOBURN	MA	01801	MIDDLESEX	USA	Digestive Diseases and Nutrition Research	000	4	12/24/2009	NON-COMPETING CONTINUATION	$0
														Subtotal = $96,281

Issue Date FY: 2008 ( Subtotal = $394,714 )
2008	2008	ORGANIX, INC	240 SALEM STREET	WOBURN	MA	01801	MIDDLESEX	USA	Digestive Diseases and Nutrition Research	000	4	8/20/2008	NON-COMPETING CONTINUATION	$394,714
														Subtotal = $394,714

Issue Date FY: 2007 ( Subtotal = $436,879 )
2007	2007	ORGANIX, INC	240 SALEM STREET	WOBURN	MA	01801	MIDDLESEX	USA	Digestive Diseases and Nutrition Research	000	3	9/1/2007	COMPETING CONTINUATION	$436,879
														Subtotal = $436,879

Grand Total All Awards = $927,874

Top

All Categories

About

Search

Reports

Data Submission

Award Information

INDOLE ANALOGS AS NOVEL APPETITE SUPPRESSANTS

Award Number: R44DK065322

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/20/2010

PERIOD OF PERFORMANCE END DATE: 06/30/2010

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer